Pfizer has announced that its vaccine is 95% effective on the basis of its Phase-3 trials. On Friday, Pfizer said that it is asking US regulators to allow the emergency use of its Covid-19 vaccine.
The company announced that they will submit a request to the US Food and Drug Administration (FDA) for Emergency Use Authorisation, which will potentially enable the use of the vaccine in high-risk populations in the US by mid to end of December 2020.
“Our work to deliver a safe and effective vaccine has never been more urgent, as we continue to see an alarming rise in the number of cases of Covid-19 globally. Filing in the US represents a critical milestone in our journey to deliver a Covid-19 vaccine to the world and we now have a more complete picture of both the efficacy and safety profile of our vaccine, giving us confidence in its potential,” said Dr Albert Borla, Pfizer CEO and chairman.